Search
Adaptive Biotechnologies Corp
ADPTAdd to Watchlist
27.670USD
+0.990+3.71%
Close 09-16 16:00（ET）
4.41BMarket Cap
LossP/E TTM
Adaptive Biotechnologies Corp (ADPT) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Adaptive Biotechnologies Corp in the past month.
Buy
3 Strong Buy
4 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
24.750USD-7.23%
ADPT Analyst Recommendation Trends
In the current month, ADPT has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ADPT average Analyst price target in the last month is 24.750.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
8
8
8
8
8
ADPT Analyst Rating for Peer Comparison
Updated: Sep 16, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, ADPT EPS is projected to reach -0.100 in FY2026Q3, following reported EPS of -0.249 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.18
-0.16
-0.13
-0.10
-0.07
Actual
-0.09
-0.13
-0.25
--
--
Surprise
+51.08%
+19.49%
-86.09%
--
--
FAQs
What is Adaptive Biotechnologies Corp's expected revenue for the next quarter?
Adaptive Biotechnologies Corp's expected revenue is 71.59M.
What is Adaptive Biotechnologies Corp's price target?
Analysts forecast that Adaptive Biotechnologies Corp's price target is USD 24.75, with the highest forecast at USD 28.00 and the lowest forecast at USD 21.00.
How have Adaptive Biotechnologies CorpADPT's recent earnings per share performed?
The market expectation was USD -0.25, while Adaptive Biotechnologies CorpADPT's earnings per share (EPS) for the previous quarter was USD -0.13. EPS for the next quarter is expected at USD -0.10.
What is the analyst rating for Adaptive Biotechnologies Corp?
Based on the ratings of Adaptive Biotechnologies Corp's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.